Delivery Order SPE2DB20D2014-SPE2DB25FC59X
- Not listed
- The Defense Logistics Agency awarded a $17,598.50 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 1, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $5,344.02 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for RINVOQ ER 30 mg tablets (30-count units). This firm fixed price contract, which represents a child award under a larger indefinite delivery vehicle, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 31, 2025. The award was competitively awarded without set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $10,772.76 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 25, 2025, with completion expected by July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a procurement of pharmaceutical inventory supporting military healthcare operations. The contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $3,111.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count) on July 14, 2025, with completion due July 15, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a $51,202.00 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 17, 2025, with an ultimate completion date of July 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $32,555.23 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $4,684.70 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 4, 2025, with completion scheduled for June 5, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating open competitive award. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and this delivery...
- The Defense Logistics Agency awarded a delivery order valued at $117,970.28 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract, indicating it falls under a larger indefinite delivery vehicle. The product will be performed and delivered from AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. This delivery order, valued at $43,045.46, represents a firm fixed-price contract with an ultimate completion date of August 29, 2025. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to meet federal procurement requirements in open competition. The place of...
- The Defense Logistics Agency awarded a $23,543.70 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is scheduled for completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC59XDelivery Order
The Defense Logistics Agency awarded a $17,245.57 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with a completion date of July 31, 2025, and represents a delivery order under the company's larger pharmaceutical supply agreement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is a child contract under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999.999 billion vehicle that runs through December 2026 and serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, supplies a broad portfolio of brand-name and generic medications, vaccines, and medical devices to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company consistently competes for and wins federal pharmaceutical contracts through open competition, demonstrating its capability to meet stringent federal medical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.2k | 7/30/25 |